Compare UTF & GLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | UTF | GLSI |
|---|---|---|
| Founded | 2004 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 123.9M |
| IPO Year | N/A | 2020 |
| Metric | UTF | GLSI |
|---|---|---|
| Price | $26.86 | $26.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $50.00 |
| AVG Volume (30 Days) | 171.7K | ★ 639.1K |
| Earning Date | 01-01-0001 | 11-14-2025 |
| Dividend Yield | ★ 7.19% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.84 | N/A |
| Revenue | ★ $138,636,669.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $9.16 | ★ N/A |
| Revenue Growth | ★ 19.80 | N/A |
| 52 Week Low | $22.05 | $7.78 |
| 52 Week High | $26.53 | $34.10 |
| Indicator | UTF | GLSI |
|---|---|---|
| Relative Strength Index (RSI) | 81.58 | 50.41 |
| Support Level | $25.84 | $25.68 |
| Resistance Level | $26.27 | $30.13 |
| Average True Range (ATR) | 0.25 | 3.14 |
| MACD | 0.05 | -0.80 |
| Stochastic Oscillator | 97.86 | 20.84 |
Cohen & Steers Infrastructure Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is total return with an emphasis on income. It invests majority of its managed assets in securities issued by infrastructure companies, which consists of utilities, pipelines, toll roads, airports, railroads, ports, telecommunications companies, and other infrastructure companies, under normal market conditions.
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9 amino acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including expression in 75 percent of breast cancers at low (1+), intermediate (2+), and high (3+ or over-expressor) levels. The combination of GP2 + GM-CSF is called GLSI-100. The company is currently expanding Flamingo-01 into Europe with plans to open up to 150 sites globally.